Skip to main content
. 2022 Mar 10;77(1):152–162. doi: 10.1016/j.jhep.2022.02.015

Fig. 3.

Fig. 3

Anti-SARS-CoV-2 s-RBD antibody titers evaluated in COVID-19-naïve patients who did or did not receive mycophenolate mofetil.

Antibody titers were measured 3 weeks (19 days) after the first dose of Pfizer-BioNTech® BNT162b2 vaccine, and after 1 month (31±2 days), 4 months (125±5 days), and 6 months (165±4 days) following the second vaccine dose with regards to the inclusion (light blue circles) or the exclusion (white circles) of mycophenolate mofetil monotherapy or in combination with other immunosuppressive drugs. Positive responders to vaccination were defined as those having reached an antibody titer ≥0.8 U/ml. Medians of antibody titers are reported for each time point, and the statistical analysis was performed by means of a non-parametric rank-sum (Mann-Whitney) test.